| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 20 | 2025 | 183 | 8.120 |
Why?
|
| Liver Neoplasms | 30 | 2025 | 1381 | 5.700 |
Why?
|
| Neuroblastoma | 24 | 2021 | 550 | 2.440 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2024 | 984 | 1.540 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2024 | 97 | 1.260 |
Why?
|
| Sarcoma | 6 | 2024 | 207 | 1.100 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 728 | 1.070 |
Why?
|
| Margins of Excision | 2 | 2024 | 57 | 1.060 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 76 | 0.940 |
Why?
|
| Child | 59 | 2025 | 25783 | 0.880 |
Why?
|
| Sarcoma, Synovial | 1 | 2024 | 22 | 0.880 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 58 | 0.830 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2022 | 106 | 0.830 |
Why?
|
| Infant | 35 | 2025 | 13049 | 0.800 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2024 | 1304 | 0.770 |
Why?
|
| Humans | 110 | 2025 | 132247 | 0.750 |
Why?
|
| Prognosis | 19 | 2025 | 5016 | 0.740 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 45 | 0.730 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 12 | 0.710 |
Why?
|
| Hepatectomy | 4 | 2023 | 118 | 0.690 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 23 | 0.690 |
Why?
|
| Peritonitis | 1 | 2021 | 76 | 0.690 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 50 | 0.690 |
Why?
|
| Adolescent | 40 | 2025 | 20557 | 0.670 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 57 | 0.670 |
Why?
|
| Child, Preschool | 35 | 2025 | 14736 | 0.670 |
Why?
|
| Retrospective Studies | 38 | 2025 | 17395 | 0.670 |
Why?
|
| Metastasectomy | 2 | 2020 | 11 | 0.650 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2020 | 34 | 0.650 |
Why?
|
| Cell Line, Tumor | 23 | 2025 | 3691 | 0.640 |
Why?
|
| Doxorubicin | 11 | 2024 | 303 | 0.610 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 1541 | 0.600 |
Why?
|
| Pneumonectomy | 2 | 2021 | 148 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2021 | 770 | 0.550 |
Why?
|
| Female | 67 | 2025 | 70785 | 0.540 |
Why?
|
| Liver Transplantation | 3 | 2023 | 1102 | 0.540 |
Why?
|
| Databases, Factual | 8 | 2019 | 1234 | 0.520 |
Why?
|
| Up-Regulation | 2 | 2021 | 881 | 0.520 |
Why?
|
| Treatment Outcome | 19 | 2025 | 13027 | 0.520 |
Why?
|
| Indocyanine Green | 3 | 2024 | 63 | 0.510 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 325 | 0.490 |
Why?
|
| Cell Proliferation | 13 | 2025 | 2511 | 0.480 |
Why?
|
| Male | 55 | 2025 | 65012 | 0.470 |
Why?
|
| Dipeptides | 2 | 2016 | 65 | 0.470 |
Why?
|
| Postoperative Complications | 7 | 2021 | 3139 | 0.470 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 4 | 0.470 |
Why?
|
| Liver | 3 | 2024 | 1797 | 0.460 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 18 | 0.460 |
Why?
|
| Kidney Neoplasms | 4 | 2025 | 451 | 0.460 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 34 | 0.450 |
Why?
|
| Wilms Tumor | 3 | 2025 | 119 | 0.450 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.450 |
Why?
|
| Survival Rate | 13 | 2025 | 2196 | 0.450 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 40 | 0.450 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 5410 | 0.430 |
Why?
|
| N-Myc Proto-Oncogene Protein | 4 | 2021 | 66 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2024 | 998 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2025 | 2062 | 0.390 |
Why?
|
| Chronic Pain | 1 | 2015 | 148 | 0.390 |
Why?
|
| Apoptosis | 12 | 2021 | 1901 | 0.390 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 702 | 0.390 |
Why?
|
| Abdominal Pain | 1 | 2015 | 314 | 0.380 |
Why?
|
| Combined Modality Therapy | 8 | 2024 | 1294 | 0.380 |
Why?
|
| Infant, Newborn | 20 | 2025 | 8548 | 0.380 |
Why?
|
| Biliary Atresia | 2 | 2025 | 206 | 0.370 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 313 | 0.370 |
Why?
|
| Ovarian Neoplasms | 3 | 2025 | 462 | 0.370 |
Why?
|
| Analgesia, Epidural | 2 | 2022 | 29 | 0.360 |
Why?
|
| Electricity | 1 | 2011 | 10 | 0.360 |
Why?
|
| Hemangioma | 2 | 2018 | 97 | 0.350 |
Why?
|
| Crystallization | 1 | 2011 | 89 | 0.350 |
Why?
|
| Neoplasm Staging | 10 | 2022 | 1365 | 0.350 |
Why?
|
| Lasers | 1 | 2011 | 117 | 0.340 |
Why?
|
| Alanine | 1 | 2011 | 159 | 0.340 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2019 | 127 | 0.330 |
Why?
|
| Thoracic Neoplasms | 3 | 2021 | 37 | 0.310 |
Why?
|
| Survival Analysis | 9 | 2021 | 1574 | 0.300 |
Why?
|
| Mice | 19 | 2024 | 18507 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 608 | 0.300 |
Why?
|
| Optical Imaging | 2 | 2021 | 73 | 0.300 |
Why?
|
| Pancreatectomy | 3 | 2022 | 149 | 0.300 |
Why?
|
| Osteosarcoma | 3 | 2021 | 263 | 0.290 |
Why?
|
| Surgical Oncology | 3 | 2024 | 13 | 0.290 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 486 | 0.280 |
Why?
|
| Animals | 24 | 2024 | 34850 | 0.270 |
Why?
|
| Cell Survival | 6 | 2021 | 868 | 0.260 |
Why?
|
| Biopsy | 3 | 2018 | 1288 | 0.260 |
Why?
|
| Reoperation | 2 | 2024 | 852 | 0.260 |
Why?
|
| Mice, Nude | 9 | 2021 | 755 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 3 | 2015 | 15 | 0.260 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 81 | 0.260 |
Why?
|
| Quinazolines | 2 | 2019 | 187 | 0.260 |
Why?
|
| Dual-Specificity Phosphatases | 3 | 2015 | 24 | 0.260 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 125 | 0.250 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 66 | 0.250 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2006 | 45 | 0.240 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 31 | 0.240 |
Why?
|
| Vincristine | 2 | 2024 | 196 | 0.240 |
Why?
|
| Thyroidectomy | 2 | 2017 | 102 | 0.240 |
Why?
|
| Carcinoma | 4 | 2016 | 300 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 396 | 0.240 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2025 | 19 | 0.230 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2017 | 446 | 0.230 |
Why?
|
| Gene Knockdown Techniques | 4 | 2021 | 398 | 0.230 |
Why?
|
| Quinolines | 2 | 2017 | 121 | 0.230 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 79 | 0.230 |
Why?
|
| Protein Phosphatase 2 | 1 | 2025 | 28 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 445 | 0.230 |
Why?
|
| Appendectomy | 1 | 2025 | 92 | 0.220 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2025 | 60 | 0.220 |
Why?
|
| Rhabdomyosarcoma | 2 | 2017 | 215 | 0.220 |
Why?
|
| Acetylcysteine | 1 | 2025 | 82 | 0.220 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2019 | 142 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1597 | 0.220 |
Why?
|
| Etoposide | 4 | 2019 | 121 | 0.220 |
Why?
|
| Teratoma | 1 | 2025 | 129 | 0.210 |
Why?
|
| Appendicitis | 1 | 2025 | 138 | 0.210 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 60 | 0.210 |
Why?
|
| Thoracoscopy | 2 | 2021 | 43 | 0.210 |
Why?
|
| Adult | 17 | 2024 | 31614 | 0.210 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 86 | 0.200 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 251 | 0.200 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 956 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1348 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3853 | 0.190 |
Why?
|
| Dependovirus | 1 | 2024 | 154 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 665 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 240 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1018 | 0.190 |
Why?
|
| Esophageal Stenosis | 1 | 2002 | 46 | 0.190 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2025 | 375 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 62 | 0.190 |
Why?
|
| Heart Defects, Congenital | 3 | 2024 | 1866 | 0.180 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 19 | 0.180 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 2021 | 9 | 0.180 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 94 | 0.180 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 589 | 0.180 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 6 | 0.180 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 17 | 0.180 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Recurrence | 2 | 2023 | 1453 | 0.180 |
Why?
|
| Gastric Dilatation | 1 | 2021 | 4 | 0.180 |
Why?
|
| Superior Mesenteric Artery Syndrome | 1 | 2021 | 5 | 0.180 |
Why?
|
| Cyanosis | 1 | 2001 | 43 | 0.170 |
Why?
|
| Young Adult | 13 | 2025 | 9966 | 0.170 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 1829 | 0.170 |
Why?
|
| Pancreas | 1 | 2022 | 222 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 1461 | 0.170 |
Why?
|
| Monitoring, Intraoperative | 1 | 2001 | 132 | 0.170 |
Why?
|
| Ultrasonography | 3 | 2025 | 988 | 0.170 |
Why?
|
| Heterografts | 5 | 2024 | 199 | 0.160 |
Why?
|
| Carbon Dioxide | 1 | 2001 | 275 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 384 | 0.160 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 65 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 96 | 0.160 |
Why?
|
| Drug Synergism | 5 | 2019 | 235 | 0.160 |
Why?
|
| Nephrectomy | 2 | 2018 | 180 | 0.160 |
Why?
|
| Thoracotomy | 1 | 2020 | 111 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2017 | 85 | 0.160 |
Why?
|
| Piperidones | 1 | 2019 | 7 | 0.150 |
Why?
|
| Thoracic Wall | 2 | 2019 | 40 | 0.150 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 223 | 0.150 |
Why?
|
| Signal Transduction | 9 | 2021 | 4720 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 255 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2021 | 221 | 0.150 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 56 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2019 | 52 | 0.150 |
Why?
|
| Cyclin D1 | 1 | 2018 | 113 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2021 | 359 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 816 | 0.140 |
Why?
|
| Gene Dosage | 1 | 2020 | 449 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2020 | 3736 | 0.140 |
Why?
|
| Dysgerminoma | 1 | 2017 | 4 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 59 | 0.140 |
Why?
|
| Consensus | 1 | 2021 | 658 | 0.140 |
Why?
|
| Age Factors | 6 | 2019 | 2923 | 0.140 |
Why?
|
| Ascites | 1 | 2018 | 103 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 309 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 207 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 12 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 613 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 133 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1966 | 0.130 |
Why?
|
| Aniline Compounds | 1 | 2017 | 20 | 0.130 |
Why?
|
| Fertility Preservation | 1 | 2017 | 58 | 0.130 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2016 | 35 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 26 | 0.130 |
Why?
|
| Sacroiliac Joint | 1 | 2016 | 4 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4690 | 0.130 |
Why?
|
| Neurofibrosarcoma | 1 | 2016 | 5 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 223 | 0.130 |
Why?
|
| United States | 11 | 2025 | 11669 | 0.130 |
Why?
|
| Sacrum | 1 | 2016 | 31 | 0.130 |
Why?
|
| Spinal Nerve Roots | 1 | 2016 | 19 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 685 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 32 | 0.130 |
Why?
|
| Pelvic Bones | 1 | 2016 | 28 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 132 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 1128 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2016 | 55 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2017 | 94 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2166 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 41 | 0.130 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 119 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1683 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 257 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 92 | 0.120 |
Why?
|
| Nitriles | 1 | 2017 | 155 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2017 | 127 | 0.120 |
Why?
|
| Gene Amplification | 2 | 2014 | 240 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2015 | 11 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 61 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2001 | 523 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 40 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2019 | 248 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 111 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2015 | 11 | 0.110 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 39 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2015 | 24 | 0.110 |
Why?
|
| Appendiceal Neoplasms | 1 | 2015 | 20 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 24 | 0.110 |
Why?
|
| Necrosis | 1 | 2015 | 210 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2015 | 119 | 0.110 |
Why?
|
| Parathyroidectomy | 1 | 2014 | 50 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 243 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Zearalenone | 1 | 2013 | 6 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2014 | 39 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 87 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1965 | 0.100 |
Why?
|
| Gastrostomy | 1 | 2014 | 92 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 491 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 201 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 2552 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 133 | 0.100 |
Why?
|
| Lipoblastoma | 1 | 2013 | 6 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 51 | 0.100 |
Why?
|
| alpha-Fetoproteins | 1 | 2014 | 134 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 69 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 97 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 177 | 0.100 |
Why?
|
| Health Resources | 1 | 2014 | 135 | 0.100 |
Why?
|
| Base Sequence | 2 | 2009 | 2900 | 0.100 |
Why?
|
| Adenoma | 1 | 2014 | 146 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 565 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 263 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 2681 | 0.100 |
Why?
|
| Intestinal Perforation | 1 | 2013 | 56 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 140 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 724 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2014 | 1612 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3771 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2021 | 5176 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 31 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2025 | 2680 | 0.090 |
Why?
|
| Transfection | 2 | 2014 | 996 | 0.090 |
Why?
|
| Thermogravimetry | 1 | 2011 | 6 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2015 | 418 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 141 | 0.090 |
Why?
|
| Fundoplication | 2 | 2002 | 70 | 0.090 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 44 | 0.090 |
Why?
|
| Vibration | 1 | 2011 | 29 | 0.090 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2011 | 38 | 0.090 |
Why?
|
| Salivation | 1 | 2011 | 6 | 0.090 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 105 | 0.090 |
Why?
|
| Neurons | 1 | 2021 | 2012 | 0.090 |
Why?
|
| Glycopyrrolate | 1 | 2011 | 10 | 0.090 |
Why?
|
| Esophagoplasty | 1 | 2011 | 13 | 0.090 |
Why?
|
| Chest Tubes | 1 | 2011 | 37 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 623 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 348 | 0.090 |
Why?
|
| Anastomotic Leak | 1 | 2011 | 33 | 0.090 |
Why?
|
| Intestines | 1 | 2015 | 606 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2011 | 35 | 0.090 |
Why?
|
| Operative Time | 2 | 2021 | 192 | 0.090 |
Why?
|
| Length of Stay | 3 | 2025 | 1382 | 0.080 |
Why?
|
| Mutation | 3 | 2022 | 6250 | 0.080 |
Why?
|
| Esophageal Atresia | 1 | 2011 | 52 | 0.080 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2011 | 48 | 0.080 |
Why?
|
| Analgesics | 2 | 2022 | 127 | 0.080 |
Why?
|
| Incidence | 4 | 2025 | 3376 | 0.080 |
Why?
|
| Age Distribution | 3 | 2016 | 437 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 387 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 297 | 0.080 |
Why?
|
| SEER Program | 2 | 2025 | 220 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 954 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 89 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 897 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 109 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 2314 | 0.070 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 274 | 0.070 |
Why?
|
| Computational Biology | 2 | 2014 | 876 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2014 | 700 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1671 | 0.070 |
Why?
|
| Infant, Premature | 2 | 2019 | 843 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 3093 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 471 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 128 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2007 | 134 | 0.060 |
Why?
|
| Esophagus | 2 | 2011 | 234 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 234 | 0.060 |
Why?
|
| Texas | 3 | 2023 | 3632 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1410 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2961 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2022 | 590 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2017 | 167 | 0.060 |
Why?
|
| Sirolimus | 2 | 2017 | 241 | 0.060 |
Why?
|
| COS Cells | 1 | 2005 | 268 | 0.060 |
Why?
|
| Ribonuclease III | 1 | 2025 | 99 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 162 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2005 | 301 | 0.060 |
Why?
|
| Catalytic Domain | 1 | 2005 | 179 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 16 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 144 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 147 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2024 | 35 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 636 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 651 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2019 | 799 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2024 | 76 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 902 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 811 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 117 | 0.050 |
Why?
|
| Registries | 2 | 2025 | 1591 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3046 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2139 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2024 | 239 | 0.050 |
Why?
|
| Morphine | 1 | 2022 | 85 | 0.050 |
Why?
|
| Dilatation | 1 | 2002 | 71 | 0.050 |
Why?
|
| Myofibroma | 1 | 2021 | 9 | 0.050 |
Why?
|
| Bays | 1 | 2021 | 7 | 0.050 |
Why?
|
| Pulmonary Blastoma | 1 | 2021 | 12 | 0.050 |
Why?
|
| Aged | 5 | 2019 | 21482 | 0.050 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2001 | 4 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 400 | 0.050 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2001 | 32 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2025 | 425 | 0.040 |
Why?
|
| Tidal Volume | 1 | 2001 | 41 | 0.040 |
Why?
|
| ARNTL Transcription Factors | 1 | 2021 | 45 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1444 | 0.040 |
Why?
|
| Cell Movement | 1 | 2025 | 890 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 60 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2669 | 0.040 |
Why?
|
| Probability | 1 | 2001 | 322 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 124 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 20 | 0.040 |
Why?
|
| Duodenum | 1 | 2021 | 113 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 82 | 0.040 |
Why?
|
| Middle Aged | 5 | 2019 | 29021 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 6568 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 44 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2019 | 49 | 0.040 |
Why?
|
| Foot Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 2019 | 8 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2025 | 1034 | 0.040 |
Why?
|
| Protein Unfolding | 1 | 2019 | 13 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 51 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 720 | 0.040 |
Why?
|
| Extremities | 1 | 2019 | 83 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 306 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 104 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 421 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1285 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 148 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 916 | 0.040 |
Why?
|
| para-Aminobenzoates | 1 | 2017 | 5 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2020 | 250 | 0.030 |
Why?
|
| Algorithms | 1 | 2005 | 1725 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1883 | 0.030 |
Why?
|
| Pediatrics | 2 | 2017 | 1210 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2017 | 42 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 1284 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 302 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 234 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 426 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 316 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 252 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 28 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 29 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 153 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 78 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 207 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 50 | 0.030 |
Why?
|
| Kidney | 2 | 2015 | 1338 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 604 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 569 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 796 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 178 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 174 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 61 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 141 | 0.030 |
Why?
|
| Appendix | 1 | 2015 | 15 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 296 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 6451 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7138 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 173 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 509 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 588 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 94 | 0.030 |
Why?
|
| Neural Prostheses | 1 | 2014 | 4 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 24 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 69 | 0.030 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 219 | 0.030 |
Why?
|
| Sciatic Nerve | 1 | 2014 | 62 | 0.030 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 18 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 249 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 275 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 327 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 120 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 138 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2451 | 0.030 |
Why?
|
| Nerve Regeneration | 1 | 2014 | 85 | 0.030 |
Why?
|
| Liposarcoma | 1 | 2013 | 23 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 689 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1354 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 565 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 618 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 579 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 137 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 103 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 774 | 0.020 |
Why?
|
| Thoracostomy | 1 | 2011 | 27 | 0.020 |
Why?
|
| Colostomy | 1 | 2011 | 28 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 666 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 368 | 0.020 |
Why?
|
| Anal Canal | 1 | 2011 | 82 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 523 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 767 | 0.020 |
Why?
|
| Spine | 1 | 2011 | 147 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 761 | 0.020 |
Why?
|
| Limb Deformities, Congenital | 1 | 2011 | 112 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2009 | 27 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 862 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 166 | 0.020 |
Why?
|
| Benzazepines | 1 | 2009 | 48 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 210 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 906 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1841 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 312 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 818 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 780 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3607 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3018 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 1099 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 10945 | 0.010 |
Why?
|